CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.

John Climaco

CNS Pharmaceuticals, Inc.

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Anavex Life Sciences Corp.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. related to a completed Phase 1 trial with Berubicin in GBM which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in progression-free survival. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 2020. In the second half of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland.  Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500-times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information, please visit www.cnspharma.com.

Happy Thanksgiving from all of us at CNS Pharmaceuticals! We hope you enjoy a day of good company and good food.

Florida Girl, 8, Girl, Spends Holiday In DC For Rare Brain Cancer Treatment  https://ibn.fm/7js7F

Industry News:    Brain Cancer Thrives By Hijacking Mechanisms To Boost Synapse Strength  https://ibn.fm/dTSps     #braincancer  #glioblastoma #neuro-oncology

CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy

https://bit.ly/3MW5gmv 
#GlioblastomaMultiforme #GBM #Oncology #Glioblastoma

Industry News:   Finger-prick Test Could Help Spot Brain Cancer Recurrence Sooner  https://ibn.fm/H3BYY    #braincancer  #glioblastoma #neuro-oncology

Meet our dedicated, experienced team here: https://bit.ly/3tCAjx9 

#GlioblastomaMultiforme #GBM #Oncology #Glioblastoma

Industry News:    Actor Had Brain Tumor The Size Of A Lime  https://ibn.fm/gEjkC    #braincancer  #glioblastoma #neuro-oncology

Watch this video on how our lead product candidate, Berubicin is designed to work: https://bit.ly/3ZWWubF  

#GlioblastomaMultiforme #GBM #Oncology #Glioblastoma

CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End

https://bit.ly/46fHoB9 
 #GlioblastomaMultiforme #GBM #Oncology #Glioblastoma

Industry News:   Lung Cancer Cells Covertly Thrive In Brain Under Guise Of Protection, Stanford Medicine Study Finds  https://ibn.fm/zAqz9   #braincancer  #glioblastoma #neuro-oncology

Metric
Company Name	CNS Pharmaceuticals, Inc.	Anavex Life Sciences Corp.
Symbol	CNSP	AVXL
MSH ID	COM:CNSPHARMA	COM:ANAVEX
Market	STOCKS	STOCKS
Sector	Healthcare	Healthcare
Industry	Biotechnology	Biotechnology
Country	US	US
Stage	Post-IPO Equity
Employee Count	3	40
Website	cnspharma.com	anavex.com
LinkedIn	cnspharma
Founders

Metric
Market Cap	1.52M	391.04M
Enterprise Value
Monthly Web Traffic	654
Web Traffic Growth	0.49
Valuation
Raised Capital	3M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:CNSPHARMA

CNS Pharmaceuticals, Inc.

Last Close

0.13

22/11 21:00

Market Cap

1.52M

Beta: -

Volume Today

194.47K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue